Intrinsiqs

Is Taysha Gene Therapies, Inc. overvalued?

Taysha Gene Therapies, Inc. (TSHA) — key valuation metrics and fundamentals.

No verdict
Price
$4.10
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.33B
Dividend yield
0.0%
Return on equity
-51.9%
Sector
Healthcare

See the full interactive analysis →

Fair value compares TSHA's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.